Health Care·Biotechnology·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.21 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains focused on advancing their research and development efforts. They acknowledged the challenges ahead but are optimistic about future prospects.
Management highlighted ongoing developments in their pipeline.
They expressed confidence in their long-term strategy despite current losses.
Kodiak Sciences Inc's earnings report shows a loss per share of $0.21, which was in line with expectations, though no revenue figures were disclosed. The stock reacted positively, rising 2.93%, likely due to management's optimistic outlook on their pipeline developments. Investors may be encouraged by the focus on long-term growth despite the current losses.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CRINETICS PHARMACEUT
May 13, 2019